These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 6424437)

  • 21. Proteolytic activity of alpha 2-macroglobulin-enzyme complexes toward human factor VIII/von Willebrand factor.
    Switzer ME; Gordon HJ; McKee PA
    Biochemistry; 1983 Mar; 22(6):1437-44. PubMed ID: 6188490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular biology of factor VIII/von Willebrand Factor.
    Meyer D; McKee PA; Hoyer LW; Zimmerman TS; Gralnick HR
    Thromb Haemost; 1978 Oct; 40(2):245-51. PubMed ID: 310584
    [No Abstract]   [Full Text] [Related]  

  • 23. Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid.
    Lollar P; Knutson GJ; Fass DN
    Blood; 1984 Jun; 63(6):1303-8. PubMed ID: 6426549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Factor VIII/von Willebrand factor complex (FVIII/vWF)].
    Yoshioka A
    Rinsho Byori; 1985 Feb; Spec No 61():73-85. PubMed ID: 3923232
    [No Abstract]   [Full Text] [Related]  

  • 25. Functional assembly of intrinsic coagulation proteases on monocytes and platelets. Comparison between cofactor activities induced by thrombin and factor Xa.
    McGee MP; Li LC; Hensler M
    J Exp Med; 1992 Jul; 176(1):27-35. PubMed ID: 1613461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies of von Willebrand factor: effects of different kinds of carbohydrate oxidases, SH-inhibitors and some other chemical reagents.
    Fukui H; Mikami S; Okuda T; Murashima N; Takase T
    Br J Haematol; 1977 Jun; 36(2):259-70. PubMed ID: 301402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombin-activated and factor Xa-activated human factor VIII: differences in cofactor activity and decay rate.
    Neuenschwander PF; Jesty J
    Arch Biochem Biophys; 1992 Aug; 296(2):426-34. PubMed ID: 1632634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage.
    Michnick DA; Pittman DD; Wise RJ; Kaufman RJ
    J Biol Chem; 1994 Aug; 269(31):20095-102. PubMed ID: 8051097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surface-governed molecular regulation of blood coagulation.
    Elödi S; Elödi P
    Mol Aspects Med; 1983; 6(4):291-353. PubMed ID: 6369061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).
    Pittman DD; Kaufman RJ
    Proc Natl Acad Sci U S A; 1988 Apr; 85(8):2429-33. PubMed ID: 3128786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers.
    Weiss HJ; Meyer D; Rabinowitz R; Pietu G; Girma JP; Vicic WJ; Rogers J
    N Engl J Med; 1982 Feb; 306(6):326-33. PubMed ID: 6798442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.
    Aly AM; Hoyer LW
    J Clin Invest; 1992 May; 89(5):1382-7. PubMed ID: 1569181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.
    Gralnick HR
    J Clin Invest; 1978 Aug; 62(2):496-9. PubMed ID: 307560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Structure and function of clotting factor VIII: the results of fundamental research].
    Beck EA; Furlan M
    Ther Umsch; 1979 Apr; 36(4):294-300. PubMed ID: 377554
    [No Abstract]   [Full Text] [Related]  

  • 35. A monoclonal antibody to factor IX that inhibits the factor VIII:Ca potentiation of factor X activation.
    Bajaj SP; Rapaport SI; Maki SL
    J Biol Chem; 1985 Sep; 260(21):11574-80. PubMed ID: 3930478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure - function relationship of factor VIII/von Willebrand factor. Application to the study of variant von Willebrand's disease and cryosupernatant prepared from normal plasma.
    Pietu G; Obert B; Larrieu MJ; Meyer D
    Thromb Res; 1980 Aug 15-Sep 1; 19(4-5):671-85. PubMed ID: 6777898
    [No Abstract]   [Full Text] [Related]  

  • 38. Persistent factor VIII-dependent factor X activation on endothelial cells is independent of von Willebrand factor.
    Brinkman HJ; van Mourik JA; Mertens K
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):190-6. PubMed ID: 18388497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII.
    Koppelman SJ; Hackeng TM; Sixma JJ; Bouma BN
    Blood; 1995 Aug; 86(3):1062-71. PubMed ID: 7620160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of factor VIII by factor IXa.
    Rick ME
    Blood; 1982 Sep; 60(3):744-51. PubMed ID: 6809077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.